Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
- PMID: 12850190
- DOI: 10.1016/s1470-2045(03)01137-9
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
Abstract
Despite aggressive surgical and chemotherapeutic interventions, non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death in men and women with overall cure rates of less than 15%. Recent advances in our understanding of cellular signalling and its critical role in tumorigenesis has led to the development of novel therapies which may offer new hope. In particular, the epidermal growth-factor receptor superfamily is an attractive therapeutic target because it is commonly overexpressed in malignant disease, regulates many vital cellular processes, and seems to be a negative prognostic indicator. Several selective inhibitors of this family of receptors are currently being evaluated in several cancers including NSCLC. In this review we examine current preclinical and clinical evidence on monoclonal antibodies (cetuximab, ABX-EGF, EMD72000, MAb ICR62, h-R3, MDX-447, MDX-H210, trastuzumab, and 2C4), immunoconjugates (Y10, Ua30:2, Mab806), anti-EGF vaccine (YMB2000), and tyrosine kinase inhibitors (gefitinib, erlotinib, CI1033, GW572016, EKB 569, PKI166, PD158780, and TAK 165).
Similar articles
-
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.Semin Oncol. 2005 Apr;32(2 Suppl 3):S35-41. doi: 10.1053/j.seminoncol.2005.03.008. Semin Oncol. 2005. PMID: 16015534 Review.
-
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23. doi: 10.1053/j.semtcvs.2008.09.005. Semin Thorac Cardiovasc Surg. 2008. PMID: 19038731 Review.
-
Medical treatment of non-small-cell lung cancer.Ann Oncol. 2005;16 Suppl 2:ii229-32. doi: 10.1093/annonc/mdi721. Ann Oncol. 2005. PMID: 15958463 Review. No abstract available.
-
Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.Clin Lung Cancer. 2008;9 Suppl 3:S109-15. doi: 10.3816/CLC.2008.s.016. Clin Lung Cancer. 2008. PMID: 19419924 Review.
-
Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.Cancer Nurs. 2003 Dec;26(6 Suppl):21S-25S. doi: 10.1097/00002820-200312001-00006. Cancer Nurs. 2003. PMID: 15025409 Review.
Cited by
-
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.Nat Rev Clin Oncol. 2024 Nov;21(11):818-832. doi: 10.1038/s41571-024-00939-2. Epub 2024 Sep 13. Nat Rev Clin Oncol. 2024. PMID: 39271787 Review.
-
Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure.Respir Res. 2016 Apr 20;17:42. doi: 10.1186/s12931-016-0346-3. Respir Res. 2016. PMID: 27098372 Free PMC article.
-
A transcriptional network signature characterizes lung cancer subtypes.Cancer. 2011 Jan 15;117(2):353-60. doi: 10.1002/cncr.25592. Epub 2010 Sep 13. Cancer. 2011. PMID: 20839314 Free PMC article.
-
RNA interference and nonviral targeted gene therapy of experimental brain cancer.NeuroRx. 2005 Jan;2(1):139-50. doi: 10.1602/neurorx.2.1.139. NeuroRx. 2005. PMID: 15717065 Free PMC article. Review.
-
Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities.Genes Dis. 2021 Sep 20;9(5):1181-1193. doi: 10.1016/j.gendis.2021.08.009. eCollection 2022 Sep. Genes Dis. 2021. PMID: 35873032 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
